Surgery after hormone therapy for advanced prostate cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial is testing if removing the prostate with surgery, after starting hormone therapy, helps men with advanced prostate cancer that has spread to many parts of the body. It aims to see if this approach improves outcomes compared to hormone therapy alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man between the ages of 18 and 70, or your doctor expects you to live at least 10 more years.
- You have prostate cancer that has spread to many areas, such as organs or at least 4 bones outside your spine or pelvis.
- You started hormone therapy for your newly diagnosed cancer within the last 3 months.
- You are in generally good health and can still perform daily activities (ECOG 0-2).
- You do not have certain other cancers, active infections, or conditions like severe heart problems or seizures.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial studies whether removing the prostate (cytoreductive radical prostatectomy) and targeting visible metastases with radiation can improve outcomes for men with newly diagnosed metastatic prostate cancer who are already starting apalutamide plus hormone therapy (ADT). It’s meant to see if treating “visible spots” after the initial medication helps the cancer control last longer.
This study tests if removing the prostate and giving strong hormone therapy works better than hormone therapy alone for men whose prostate cancer has spread. It aims to improve how long patients live without the cancer worsening.
This trial studies whether adding apalutamide to standard hormone therapy (ADT) improves outcomes for men with metastatic hormone-sensitive prostate cancer. Some people may also receive local treatments (like surgery or radiotherapy) to control the prostate and nearby areas.
This study tests combining targeted radiation therapy (guided by special imaging) with a hormone-blocking medication called darolutamide in men with prostate cancer that has spread to other parts of the body. The goal is to see if this combination works better than standard treatment alone.
This trial tests a shorter course of hormone therapy plus targeted radiation for prostate cancer that has spread to a few spots (oligometastatic). The goal is to see if less hormone therapy can still control the cancer effectively.
This trial tests whether removing the prostate (surgery) plus standard hormone therapy and chemotherapy can help men whose prostate cancer has spread to many places in the body. It is for men who have not yet had treatment for their cancer.
Hear when a new Metastatic Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.